At a glance
ClinicalIndex Comparison RecordN/ACompleted· 81 enrolled
Drug / intervention
REVEAL Insertable Cardiac Monitor (ICM)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Monitoring in Dialysis
Medtronic Corporate Technologies and New Ventures·interventional·Posted Jan 30, 2013·Updated Feb 15, 2021
In Brief
A clinical study evaluating REVEAL Insertable Cardiac Monitor (ICM) for End Stage Renal Disease. Completed, enrolled 81 participants across 10 sites in 2 countries.
Detailed Summary
The primary objective of this study is to estimate the proportion of hemodialysis patients experiencing clinically significant cardiac arrhythmias over a 6-month period using continuous cardiac monitoring with an implanted Medtronic Reveal Insertable Cardiac Monitor (ICM) device.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesIndia, United States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedJan 2013
Primary CompletionJul 2015
Study CompletionSep 2015
TodayJul 2026
First PostedJan 30, 2013
Enrollment StartJan 1, 2013
Primary CompletionJul 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.4 years ago
Interventions
REVEAL Insertable Cardiac Monitor (ICM)device